Faconti Luca, Abrams Louise, Jenner Bernadette, Shantsila Eduard, Partridge Sarah, Wilkinson Ian B
King's College London British Heart Foundation Centre, Department of Clinical Pharmacology, 4th Floor, North Wing, St. Thomas' Hospital, Westminster Bridge, London, SE1 7EH, UK.
Retired, at the time of writing Homerton University Hospital, Homerton Row, London, E9 6SR, UK.
J Hum Hypertens. 2025 May;39(5):313-314. doi: 10.1038/s41371-025-01004-w. Epub 2025 Apr 24.
In their review of clinical practice guidelines on the use of renin-angiotensin-aldosterone system (RAAS) inhibitors, Greenlees and Delles call for more explicit advice on the use of these drugs among women of childbearing potential, during pregnancy and breastfeeding. In response, the British and Irish Hypertension Society (BIHS) highlight the key issues for clinicians to consider when prescribing RAAS inhibitors to hypertensive women and suggest areas where further research is needed.
在对肾素-血管紧张素-醛固酮系统(RAAS)抑制剂使用的临床实践指南进行综述时,格林利斯和德莱斯呼吁针对有生育潜力的女性、孕期及哺乳期女性使用这些药物给出更明确的建议。对此,英国和爱尔兰高血压协会(BIHS)强调了临床医生在为高血压女性开具RAAS抑制剂处方时需要考虑的关键问题,并指出了需要进一步研究的领域。